Jacobs Solutions Inc.

unmute to prevent any background noise. After the speaker's remarks, there will be time. Simply press star followed by the number one on your telephone keypad. And if you'd like to withdraw your question, again, press star one. Thank you. And I would now like to turn the conference over to Bert Zubin, Senior Vice President, Investor Relations. Bert, you may begin.

Thank you, Krista, and good morning, everyone. Our earnings announcement and 10Q were filed this morning, and we have posted a slide presentation on our website, which we'll reference during the call. I would like to refer you to slide two of the presentation material for information about our forward-looking statements, non-GAAP financial measures, and operating metrics. Turning to the agenda on slide three, speaking on today's call will be Jacobs Chair and CEO Bob Pergata and CFO Bank Nathamuni. Bob will begin by providing an overview of recent activities and highlights from our first quarter results. Banks will then provide a detailed review of our financial performance, including commentary on end market trends, cash flows, and balance sheet data. Finally, Bob will provide closing remarks, and then we'll open up the call for questions. With that, I'll turn it over to our chair and CEO, Dr. Gatto.

Good day, everyone, and thank you for joining us to discuss our first quarter 2025 business performance. Starting on slide four, I want to highlight that we are excited to be hosting our 2025 Investor Day on February 18th in Miami. Our simplified structure, global delivery model, and end-to-end expertise position us extremely well to build on a great start to FY25. We see a bright future ahead as we are creating value for our shareholders over the long term, and at our investor day, we plan to lay out our vision for Jacob's next exciting chapter. We look forward to providing you with more detail in just two weeks. Turning to slide five, total gross revenue increased over 4% in Q1, with adjusted net revenue rising over 5%. GAAP EPS was negative $0.10 and includes a negative $1.16 impact from the market-to-market loss in our investment in momentum. Excluding this and other items, Q1 adjusted EPS was $1.33, an 8% decrease compared to the previous year. The year-on-year decline in adjusted EPS was a result of a favorable tax item last year that resulted in a $0.49 per share benefit in Q1 2024. Adjusted EBITDA for Q1 was $282 million, which represented a 24% year-on-year increase. We are pleased with the strong underlying business performance, and we are seeing very good traction on adjusted EBITDA margin improvement. Our trailing 12-month book-to-bill was 1.3 times as our consolidated backlog increased 19% year-over-year in Q1. We are encouraged by the trajectory we're delivering on, following two extremely strong quarters for new awards in the second half of 2024. Growth profit and backlog increased 12% year-over-year in the first quarter, reflecting back-to-back quarters of double-digit growth. Turning to slide six, I'm excited to report that during the quarter, we continue to deliver substantial wins across the business and across geographies, a testament for our market positioning, deep domain expertise, and long-term trusted client relationships. We saw solid revenue growth year over year, mainly in our infrastructure and advanced facility segments. We're demonstrating impressive revenue growth globally in water and environmental with all major geographies showing strength in Q1. Notably, during Q1, We were selected to operate, maintain, and provide capital project program support for the water treatment system managed by JXN Water. This 10-year contract will continue to improve water service and water equity and has already provided 180,000 residents in and around Jackson, Mississippi, with more reliable drinking water. In life sciences and advanced manufacturing, we continue to deliver strong results in life sciences with double-digit net revenue growth in Q1. Our backlog in life sciences has been rising over the last 12 months, giving us good line of sight over the coming quarters. Further, market activity remains very robust, with our involvement spanning key areas such as GOP1s, monoclonal antibodies, antibody drug conjugates, and cutting edge R&D programs for leading biopharmaceutical companies. Turning to critical infrastructure. During the quarter, we achieved significant milestones on two transformative projects. First, we were selected as part of the preferred alliance for the landmark River Torrens to Darlington project in South Australia. This $15.4 billion initiative by the South Australian government will deliver a 10.5 kilometer nonstop motorway completing the 78-kilometer north-south corridor. The TDD project is poised to drive economic growth and development across Adelaide and South Australia. Additionally, we have been chosen by Ireland's National Transport Authority to deliver the Bus Connects Dublin program. This ambitious 10-year initiative will enhance public transit by developing 230 kilometers of bus priority corridors and 200 kilometers of cycling and pedestrian paths. The project not only promotes sustainable growth and climate resilience, but also strengthens connectivity in and around Dublin. We're encouraged by the increased demand for large-scale international projects and critical infrastructure to complement the momentum we've been seeing in the U.S. In summary, we are pleased with our continued progress this quarter as we execute on our strategic priorities to deliver sustainable and profitable growth. We're excited for the future and look forward to presenting our strategic vision for Jacobs over the coming years at our upcoming investor day. Now I'll turn the call over to Venk to review our financial results in further detail.